Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Posted by Geri Gentry on Nov 1st, 2026

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $274.68.

Several research firms have issued reports on AXSM. BMO Capital Markets initiated coverage on shares of Axsome Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $310.00 price target on the stock. Guggenheim lifted their price objective on shares of Axsome Therapeutics from $260.00 to $275.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Zacks Research upgraded shares of Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Truist Financial upped their target price on shares of Axsome Therapeutics from $200.00 to $285.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Thursday, October 15th.

Get Our Latest Stock Report on AXSM

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the sale, the chief operating officer owned 10,000 shares of the company’s stock, valued at $2,086,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 4,660 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $213.95, for a total value of $997,007.00. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,546,644.55. This represents a 39.20% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 59,664 shares of company stock worth $12,624,805. 20.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axsome Therapeutics

Large investors have recently modified their holdings of the stock. Hollencrest Capital Management boosted its position in shares of Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock valued at $34,000 after acquiring an additional 160 shares during the period. ABS Investment Management LLC acquired a new position in shares of Axsome Therapeutics in the second quarter valued at about $171,339,000. ABS Direct Equity Fund LLC acquired a new position in shares of Axsome Therapeutics in the second quarter valued at about $60,000. Silvant Capital Management LLC bought a new position in Axsome Therapeutics during the second quarter worth about $66,000. Finally, Parkside Financial Bank & Trust increased its position in Axsome Therapeutics by 505.4% during the second quarter. Parkside Financial Bank & Trust now owns 339 shares of the company’s stock worth $83,000 after acquiring an additional 283 shares during the period. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $144.43 on Tuesday. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. Axsome Therapeutics has a 12 month low of $123.50 and a 12 month high of $260.19. The company’s fifty day simple moving average is $184.76 and its 200-day simple moving average is $198.93. The firm has a market cap of $7.57 billion, a PE ratio of -38.51 and a beta of 0.86.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. The business had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. Equities research analysts expect that Axsome Therapeutics will post -3.04 EPS for the current fiscal year.

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.